JAMA:bamlanivimab- etesevimab联合治疗可降低新冠肺炎患者病毒载量

2021-01-25 MedSci原创 MedSci原创

对于无需住院的新冠肺炎轻中度症状患者,中和抗体bamlanivimab- etesevimab联合治疗可显著降低病毒载量,而bamlanivimab单药疗法对病毒载量的影响不显著

严重急性呼吸综合征冠状病毒2(SARS-Cov-2) 感染者的临床症状十分广泛,包括咳嗽、发烧、不适、肌炎及胃肠道症状,重症患者可进展为急性呼吸窘迫综合征。目前已知的重症危险因素包括男性、高龄、血管疾病、肺病、高血压、糖尿病或肥胖人群,而具有高风险因素的轻症患者可在较短的时间内进展为重症。中和抗体Bamlanivimab以获得FDA紧急使用授权(EUA),用于中重度COVID-19成人患者治疗及危重高风险人群的预防治疗。近日研究人员比较了Bamlanivimab单药或与中和单抗Etesevimab联用,对轻中度新冠肺炎患者的治疗效果。
 
BLAZE-1研究为一项II-III期临床研究,在美国49个医疗中心开展,613名新冠肺炎检测阳性患者参与,患者临床症状评估为轻中度。患者于2020年6月17日-8月21日间,接受Bamlanivimab单药或安慰剂治疗,随后接受Bamlanivimab单药或Bamlanivimab-Etesevimab联合治疗,其中101名患者接受单次700mg Bamlanivimab治疗,107名患者接受2800mg Bamlanivimab治疗,101名患者接受7000mg Bamlanivimab治疗,112名患者接受2800mg Bamlanivimab联合2800mg Etesevimab,156名患者接受安慰剂。研究的主要终点为第11天病毒载量Log值变化。
 
患者平均年龄44.7岁,女性占54.6%,92.4%的患者完成研究。700mg Bamlanivimab治疗组第11天,病毒载量Log值与基线相比,下降3.72,2800mg组下降了4.08,而7000mg组下降了3.49,Bamlanivimab-Etesevimab联合治疗组下降了4.37,而安慰剂组下降了3.80,与安慰剂相比,各组的病毒载量Log值变化分别为0.09、-0.27、0.31以及-0.57。在84个次要终点中,10个终点有统计学意义,其中新冠肺炎住院及急诊率:安慰剂组为5.8%,700mg Bamlanivimab治疗组为1.0%,2800mg Bamlanivimab组为1.9%,而7000mg Bamlanivimab组为2.0%,Bamlanivimab-Etesevimab联合治疗组为0.9%。9名患者治疗后立即出现过敏反应,其中安慰剂组1例。研究期间未发生患者死亡。
 
研究认为,对于无需住院的新冠肺炎轻中度症状患者,中和抗体bamlanivimab- etesevimab联合治疗可显著降低病毒载量,而bamlanivimab单药疗法对病毒载量的影响不显著
 
原始出处:
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2021292, encodeId=1ff8202129292, content=<a href='/topic/show?id=699610138b7' target=_blank style='color:#2F92EE;'>#IVIM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10138, encryptionId=699610138b7, topicName=IVIM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Wed Oct 06 08:22:15 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007927, encodeId=4eb0200e927c8, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Mar 19 16:22:15 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965505, encodeId=e40896550581, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Fri May 14 11:44:40 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912524, encodeId=9cf81912524ce, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Mar 18 08:22:15 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313818, encodeId=cbf413138188d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491170, encodeId=0c0514911e043, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029034, encodeId=49831029034ef, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036419, encodeId=54d6103641965, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2021292, encodeId=1ff8202129292, content=<a href='/topic/show?id=699610138b7' target=_blank style='color:#2F92EE;'>#IVIM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10138, encryptionId=699610138b7, topicName=IVIM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Wed Oct 06 08:22:15 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007927, encodeId=4eb0200e927c8, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Mar 19 16:22:15 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965505, encodeId=e40896550581, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Fri May 14 11:44:40 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912524, encodeId=9cf81912524ce, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Mar 18 08:22:15 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313818, encodeId=cbf413138188d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491170, encodeId=0c0514911e043, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029034, encodeId=49831029034ef, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036419, encodeId=54d6103641965, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-03-19 tamgche
  3. [GetPortalCommentsPageByObjectIdResponse(id=2021292, encodeId=1ff8202129292, content=<a href='/topic/show?id=699610138b7' target=_blank style='color:#2F92EE;'>#IVIM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10138, encryptionId=699610138b7, topicName=IVIM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Wed Oct 06 08:22:15 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007927, encodeId=4eb0200e927c8, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Mar 19 16:22:15 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965505, encodeId=e40896550581, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Fri May 14 11:44:40 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912524, encodeId=9cf81912524ce, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Mar 18 08:22:15 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313818, encodeId=cbf413138188d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491170, encodeId=0c0514911e043, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029034, encodeId=49831029034ef, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036419, encodeId=54d6103641965, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-05-14 14775a26m11暂无昵称

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2021292, encodeId=1ff8202129292, content=<a href='/topic/show?id=699610138b7' target=_blank style='color:#2F92EE;'>#IVIM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10138, encryptionId=699610138b7, topicName=IVIM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Wed Oct 06 08:22:15 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007927, encodeId=4eb0200e927c8, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Mar 19 16:22:15 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965505, encodeId=e40896550581, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Fri May 14 11:44:40 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912524, encodeId=9cf81912524ce, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Mar 18 08:22:15 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313818, encodeId=cbf413138188d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491170, encodeId=0c0514911e043, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029034, encodeId=49831029034ef, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036419, encodeId=54d6103641965, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-03-18 snf701207
  5. [GetPortalCommentsPageByObjectIdResponse(id=2021292, encodeId=1ff8202129292, content=<a href='/topic/show?id=699610138b7' target=_blank style='color:#2F92EE;'>#IVIM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10138, encryptionId=699610138b7, topicName=IVIM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Wed Oct 06 08:22:15 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007927, encodeId=4eb0200e927c8, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Mar 19 16:22:15 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965505, encodeId=e40896550581, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Fri May 14 11:44:40 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912524, encodeId=9cf81912524ce, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Mar 18 08:22:15 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313818, encodeId=cbf413138188d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491170, encodeId=0c0514911e043, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029034, encodeId=49831029034ef, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036419, encodeId=54d6103641965, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2021292, encodeId=1ff8202129292, content=<a href='/topic/show?id=699610138b7' target=_blank style='color:#2F92EE;'>#IVIM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10138, encryptionId=699610138b7, topicName=IVIM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Wed Oct 06 08:22:15 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007927, encodeId=4eb0200e927c8, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Mar 19 16:22:15 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965505, encodeId=e40896550581, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Fri May 14 11:44:40 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912524, encodeId=9cf81912524ce, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Mar 18 08:22:15 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313818, encodeId=cbf413138188d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491170, encodeId=0c0514911e043, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029034, encodeId=49831029034ef, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036419, encodeId=54d6103641965, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2021292, encodeId=1ff8202129292, content=<a href='/topic/show?id=699610138b7' target=_blank style='color:#2F92EE;'>#IVIM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10138, encryptionId=699610138b7, topicName=IVIM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Wed Oct 06 08:22:15 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007927, encodeId=4eb0200e927c8, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Mar 19 16:22:15 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965505, encodeId=e40896550581, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Fri May 14 11:44:40 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912524, encodeId=9cf81912524ce, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Mar 18 08:22:15 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313818, encodeId=cbf413138188d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491170, encodeId=0c0514911e043, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029034, encodeId=49831029034ef, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036419, encodeId=54d6103641965, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-01-25 公卫新人

    新冠肺炎,疫情何时才能消失

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2021292, encodeId=1ff8202129292, content=<a href='/topic/show?id=699610138b7' target=_blank style='color:#2F92EE;'>#IVIM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10138, encryptionId=699610138b7, topicName=IVIM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Wed Oct 06 08:22:15 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007927, encodeId=4eb0200e927c8, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Mar 19 16:22:15 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965505, encodeId=e40896550581, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Fri May 14 11:44:40 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912524, encodeId=9cf81912524ce, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Mar 18 08:22:15 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313818, encodeId=cbf413138188d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491170, encodeId=0c0514911e043, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Wed Jan 27 10:22:15 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029034, encodeId=49831029034ef, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036419, encodeId=54d6103641965, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jan 25 22:22:15 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-01-25 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

2021年1月24日全球新冠肺炎(COVID-19)疫情简报,确诊超9926万,疫苗与病毒突变成为新的课题

Worldometers世界实时统计数据显示,截至北京时间2021年1月23日7时24分,全球累计确诊新冠肺炎(COVID-19)病例超过9926万例,新增544,166例,达到99,267,621例

Diabetes Care:新冠肺炎患者早期住院血糖波动与死亡之间的关系

这些结果可能对住院初期COVID-19患者的血糖控制策略的优化具有指导意义。

2021年1月25日全球新冠肺炎(COVID-19)疫情简报,确诊超9973万,疫情迎来分水岭,日新增病例被遏制

Worldometers世界实时统计数据显示,截至北京时间2021年1月25日7时44分,全球累计确诊新冠肺炎(COVID-19)病例超过9973万例,新增429,865例,达到99,730,023例

2021年1月23日全球新冠肺炎(COVID-19)疫情简报,确诊超9871万,国内5省市出现本土病例

Worldometers世界实时统计数据显示,截至北京时间2021年1月23日9时04分,全球累计确诊新冠肺炎(COVID-19)病例超过9871万例,新增647,043例,达到98,713,370例

BMJ:托珠单抗治疗对重症及危重新冠肺炎患者临床改善作用不明显

在重症或危重covid-19患者中,在标准治疗方案基础上添加托珠单抗不能改善患者15天临床结果,并且可能与死亡率增加有关

2021年1月23日24时:31个省区市新增确诊新冠肺炎病例80例,其中本土病例65例

国家卫健委消息,1月23日0—24时,31个省(自治区、直辖市)和新疆生产建设兵团报告新增确诊病例80例,其中境外输入病例15例(广东5例,上海3例,山西2例,天津1例,辽宁1例,江苏1例